AcquisitionsMay 1, 2026, 07:03 AM
ESPR to be acquired by ARCHIMED for up to $1.1B; Shareholders get $3.16/share cash
AI Summary
Esperion Therapeutics announced a definitive agreement to be acquired by ARCHIMED, a healthcare investment firm, in a transaction valued at up to approximately $1.1 billion in total equity value. Esperion shareholders will receive $3.16 per share in cash at closing, representing a 58% premium to the April 30, 2026 closing price. Additionally, shareholders will receive contingent value rights for up to $100 million in aggregate milestone payments tied to future net sales performance of its core cardiometabolic products. The transaction is expected to close in the third quarter of 2026, after which Esperion will become a privately held company.
Key Highlights
- ARCHIMED to acquire Esperion Therapeutics for up to $1.1 billion in total equity value.
- Shareholders to receive $3.16 per share in cash at closing.
- Upfront cash represents a 58% premium to Esperion's closing share price on April 30, 2026.
- Shareholders will receive contingent value rights for up to $100 million in aggregate milestone payments.
- Milestones include up to $40 million for bempedoic acid product sales and $60 million for bumetanide product sales.
- Transaction expected to close in the third quarter of 2026, subject to shareholder and regulatory approvals.
- Esperion will become a privately held company and its common stock will be delisted from Nasdaq.
- The Q1 2026 earnings conference call, previously scheduled for May 7, 2026, has been canceled.